Clinical Study on Shenqi Jiangtang Tablets(参芪降糖片)Combined with Insulin Alleviating Early Diabetic Nephropathy with Deficiency of Spleen and Kidney
Objective The current manuscript investigated the clinical activities of Shenqi Jiangtang Tablets(参芪降糖片)combined with insulin in the treatment of early diabetic nephropathy of deficiencyin spleen and kidney.Methods From September 2020 to December 2021,96 patients diagnosed as diabetic nephropathy in stage 3 due to deficiency of both spleen and kidney,and they were equally divided into the observation group and the control group with random number method.The control group was treated with insulin only,and the observation group was treated with insulin and Shenqi Jiangtang Tablets.The difference in TCM syndrome scores between the two groups before and after treatment was compared as well as the control of blood glucose,renal function and laboratory indexes four weeks after treatment.Results The total effective rate(91.67％)in the observation group was significantly higher than 74.00％in the control group with significance(P＜0.05).After treatment,the levels of FBG,2 h PG and HbA1c in the observation group were significantly lower than those in the control group(P＜0.05).After treatment,the levels of urinary mAlb,UAER,β2-MG,Cys-C,mAlb,UAER,β2-MG and Cys-C in the two groups were lower than those before treatment(P＜0.05).After treatment,the levels of VEGF,ACE and IGF-1 were all lower in the two groups than those before treatment(P＜0.05).Four weeks after treatment,the levels of VEGF,ACE and IGF-1 in the observation group were lower than those in the control group(P＜0.05).Conclusion Shenqi Jiangtang Tablets combined with insulin can significantly al-leviate the diabetic nephropathy with deficiency of spleen and kidney by stabilizing blood glucose and inhibiting kidney injury.
Shenqi Jiangtang Tablets(参芪降糖片)insulininsulin aspartdiabetic nephropathydeficiency of spleen and kidney
NETL
NSTL
万方数据
